BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Jordan M, Waxman DJ. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. BMC Cancer 2016;16:623. [PMID: 27515027 DOI: 10.1186/s12885-016-2597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Stoffel TJ, Segatto AL, Silva MM, Prestes A, Barbosa NB, Rocha JB, Loreto EL. Cyclophosphamide in Drosophila promotes genes and transposable elements differential expression and mitochondrial dysfunction. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2020;230:108718. [DOI: 10.1016/j.cbpc.2020.108718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Khan KA, Ponce de Léon JL, Benguigui M, Xu P, Chow A, Cruz-Muñoz W, Man S, Shaked Y, Kerbel RS. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. NPJ Breast Cancer 2020;6:29. [PMID: 32704531 DOI: 10.1038/s41523-020-0171-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Gewirtz DA, Tyutyunyk-Massey L, Landry JW. The potentially conflicting cell autonomous and cell non-autonomous functions of autophagy in mediating tumor response to cancer therapy. Biochem Pharmacol 2018;153:46-50. [PMID: 29408462 DOI: 10.1016/j.bcp.2018.01.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience 2016;10:689. [PMID: 27994645 DOI: 10.3332/ecancer.2016.689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
5 Villamañan L, Martínez-Escardó L, Arús C, Yuste VJ, Candiota AP. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. Int J Mol Sci 2021;22:3453. [PMID: 33810611 DOI: 10.3390/ijms22073453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Valenzuela P, Oaxaca D, Di Desidero T, Parra K, Rodriguez G, Manciu M, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G. Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. Clin Exp Med 2021;21:149-59. [PMID: 33048259 DOI: 10.1007/s10238-020-00666-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Muñoz R, Hileeto D, Cruz-Muñoz W, Wood GA, Xu P, Man S, Viloria-Petit A, Kerbel RS. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. PLoS One 2019;14:e0222580. [PMID: 31536574 DOI: 10.1371/journal.pone.0222580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, Mocioiu V, Julià-Sapé M, Pumarola M, Arús C, Candiota AP. Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites 2017;7:E20. [PMID: 28524099 DOI: 10.3390/metabo7020020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
9 Stern PL. Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017. Ther Adv Vaccines 2017;5:55-68. [PMID: 28794878 DOI: 10.1177/2051013617720659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Huang HC, Su WJ, Chiang CL, Feng JY, Huang HY, Lin CH, Lin SH, Cheng CY, Chiu CH. The predictive value of the interferon-γ release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer. Lung Cancer 2018;115:64-70. [PMID: 29290264 DOI: 10.1016/j.lungcan.2017.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Heinhuis K, Ros W, Kok M, Steeghs N, Beijnen J, Schellens J. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology 2019;30:219-35. [DOI: 10.1093/annonc/mdy551] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 33.7] [Reference Citation Analysis]
12 Liu Z, Liao Z, Chen Y, Zhou L, Huangting W, Xiao H. Research on CRISPR/system in major cancers and its potential in cancer treatments. Clin Transl Oncol 2021;23:425-33. [PMID: 32671729 DOI: 10.1007/s12094-020-02450-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tran AP, Ali Al-Radhawi M, Kareva I, Wu J, Waxman DJ, Sontag ED. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Front Immunol 2020;11:1376. [PMID: 32695118 DOI: 10.3389/fimmu.2020.01376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Wu S, Calero-Pérez P, Villamañan L, Arias-Ramos N, Pumarola M, Ortega-Martorell S, Julià-Sapé M, Arús C, Candiota AP. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. NMR Biomed 2020;33:e4229. [PMID: 31926117 DOI: 10.1002/nbm.4229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018;419:210-21. [PMID: 29414305 DOI: 10.1016/j.canlet.2018.01.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 32.7] [Reference Citation Analysis]
16 Kerbel RS, Shaked Y. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Lett 2017;400:293-304. [PMID: 28202353 DOI: 10.1016/j.canlet.2017.02.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
17 Wouters R, Bevers S, Riva M, De Smet F, Coosemans A. Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma. Cancers (Basel) 2020;13:E19. [PMID: 33374542 DOI: 10.3390/cancers13010019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Helal DO, Rouatbi N, Han S, Tzu-Wen Wang J, Walters AA, Abdel-Mottaleb MMA, Kamel AO, Geneidi AS, Awad GAS, Al-Jamal KT. A Natural Protein Based Platform for the Delivery of Temozolomide Acid to Glioma Cells. Eur J Pharm Biopharm 2021:S0939-6411(21)00262-9. [PMID: 34678408 DOI: 10.1016/j.ejpb.2021.10.007] [Reference Citation Analysis]
19 Du B, Waxman DJ. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett 2020;470:170-80. [PMID: 31765733 DOI: 10.1016/j.canlet.2019.11.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]